Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country crawled time : 15:20 save search
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2022
Published: 2023-03-29 (Crawled : 15:20) - biospace.com/
VASO | $0.2919 25.47% 23K
|
Manufacturing
|
| O: 0.0%
H: 17.83%
C: 10.31%
year corporation financial results
IMUNON Presents PLACCINE Data at Vaccine Technology Summit 2023
Published: 2023-03-22 (Crawled : 15:20) - biospace.com/
IMNN | $1.31 -1.5% -1.53% 32K
|
Manufacturing
|
| O: 0.0%
H: 2.89%
C: 0.0%
vaccine technology
Quest Diagnostics Unveils Advanced Transplant Diagnostic Services Featuring Anywhere-Access in the United States
Published: 2023-03-22 (Crawled : 15:20) - biospace.com/
DGX | News | $137.55 0.62% 0.0% 1.6M
|
Health Services
|
| O: 0.29%
H: 0.68%
C: -1.45%
services diagnostic diagnostics
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
Published: 2023-01-19 (Crawled : 15:20) - biospace.com/
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -0.13%
H: 1.27%
C: -1.85%
treatment fda fibrosis drug liver application nash
CYduct Diagnostics Inc. Provides a Corporate Outlook for 2023
Published: 2023-01-19 (Crawled : 15:20) - biospace.com/
CYDX | $0.41 -14.15% 290
|
n/a
| Email alert
Add to watchlist
diagnostics
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
ITCI 4 d | $73.02 -1.34% -1.36% 730K
|
Health Technology
|
| O: 0.79%
H: 0.86%
C: -4.97%
meeting caplyta depression
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
YMAB | $15.26 -0.52% -0.52% 160K
|
Health Technology
|
| O: 0.22%
H: 3.45%
C: -0.86%
danyelza treatment approved china
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: -1.26%
H: 8.94%
C: 5.53%
life trial
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
Published: 2022-12-06 (Crawled : 15:20) - biospace.com/
CLDX | $36.975 -2.11% -2.15% 390K
|
Health Technology
|
| O: -0.33%
H: 3.35%
C: -0.55%
global urticaria therapeutics positive study phase 2b
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
Published: 2022-11-10 (Crawled : 15:20) - biospace.com/
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: 5.31%
H: 6.88%
C: 6.88%
talen pre-clinical smart tumors
Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia
Published: 2022-10-25 (Crawled : 15:20) - biospace.com/
SEEL | $0.2971 -9.17% -10.1% 600K
|
Health Technology
|
| O: 1.47%
H: 3.54%
C: 0.55%
sls-005 therapeutics study
New FDA-Approved Labeling for Petros Pharmaceuticals’ STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy
Published: 2022-10-25 (Crawled : 15:20) - biospace.com/
PTPI | $0.635 -6.63% -7.1% 180K
|
|
| O: 9.68%
H: 45.69%
C: 26.56%
stendra
Insmed Announces Strategic Financings Totaling $775 Million
Published: 2022-10-19 (Crawled : 15:20) - biospace.com/
INSM | $25.78 2.02% 1.98% 2.5M
|
Health Technology
|
| O: -4.23%
H: 0.0%
C: -10.91%
ProPhase Labs Announces Collaboration with G42 Healthcare
Published: 2022-10-19 (Crawled : 15:20) - biospace.com/
PRPH | $5.12 -0.78% -0.78% 16K
|
Health Technology
|
| O: -2.21%
H: 0.84%
C: -8.28%
collaboration
ImmunityBio Backslides while Rigel and Amneal also Reveal Job Cuts
Published: 2022-10-11 (Crawled : 15:20) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: -11.04%
Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market
Published: 2022-05-27 (Crawled : 15:20) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 2.26%
H: 0.0%
C: 0.0%
injection market
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.